泰拉生物科学
TYRA
18.52
-0.52
-2.73%
泰拉生物科学
US · TYRA
#3032 按市值排名
上市于 2021
18.52
-0.52
-2.73%
实时 - 追踪5344个代码 - 心跳于10秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了1家。
- 机构持股总比例下降了9.6个百分点。
机构持股
- 机构持股比例
- 107.80% -9.55pp
- 机构数量
- 204 -1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund43.27%
VC/PE Fund37.14%
Hedge Fund24.26%
Individual/Insider2.28%
Public Company2.02%
Private Company0.64%
Sovereign Wealth Fund0.26%
Government Pension Fund0.20%
主要股东 截至 2026-09-15
RA Capital Management, L.P.
17.74% · 12.20M 股
FMR
12.97% · 8.92M 股
Janus Henderson Group plc
6.33% · 4.35M 股
BVF Partners L.P.
6.13% · 4.22M 股
Alta Partners LP
5.56% · 3.82M 股
Nextech Invest Ltd.
5.17% · 3.55M 股
Paradigm Biocapital Advisors LP
5.05% · 3.47M 股
TCG Crossover Management, LLC
4.73% · 3.25M 股
BlackRock
4.41% · 3.03M 股
T. Rowe Price Group, Inc.
4.05% · 2.78M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 31次买入 · 18次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| RA Capital Management, L.P. | -- | 17.74% |
| Todd Harris | Co-Founder, President, CEO, Secretary, Treasurer & Director | 1.98% |
| Daniel Bensen | Co-Founder & COO | 0.21% |
| Gilla Kaplan | Independent Director | 0.04% |
| Alan Fuhrman | Chief Financial Officer | 0.02% |
| Julia Rueb | VP of Finance & Principal Accounting Officer | 0.02% |
| Adele M. Gulfo | Director | 0.01% |
| Rehan Verjee | Independent Director | 0.00% |
| Alta Partners LP | -- | -- |
| Canaan Management, Inc. | -- | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-14 | Alan Fuhrman | Chief Financial Officer | Other Acquisition | +951 | $9.13 |
| 2026-09-14 | RA Capital Management, L.P. | -- | Open Market Derivative Acquisiti | +9,078,529 | $0.00 |
| 2026-09-14 | Todd Harris | Co-Founder, President, CEO, Secretary, Treasurer & Director | Other Acquisition | +864 | $9.13 |
| 2026-09-14 | Julia Rueb | VP of Finance & Principal Accounting Officer | Other Acquisition | +2,925 | $9.13 |
| 2026-09-08 | Rehan Verjee | Independent Director | Open Market Acquisition | +971 | $20.58 |
| 2026-05-27 | Robert J. More | Independent Director | Other Derivative Acquisition | +13,160 | $32.68 |
| 2026-05-27 | RA Capital Management, L.P. | -- | Other Derivative Acquisition | +13,160 | $32.68 |
| 2026-05-27 | Adele M. Gulfo | Director | Other Derivative Acquisition | +13,160 | $32.68 |
| 2026-05-27 | Rehan Verjee | Independent Director | Other Derivative Acquisition | +13,160 | $32.68 |
| 2026-05-27 | S. Rothenberg | Independent Director | Other Derivative Acquisition | +13,160 | $32.68 |
| 2026-05-27 | Jake Simson | Independent Director | Other Derivative Acquisition | +13,160 | $32.68 |
| 2026-05-27 | Susan Moran | Independent Director | Other Derivative Acquisition | +13,160 | $32.68 |
| 2026-05-04 | Alan Fuhrman | Chief Financial Officer | Other Acquisition | +20,000 | -- |
| 2026-05-04 | Alan Fuhrman | Chief Financial Officer | Other Derivative Acquisition | +67,000 | $33.93 |
| 2026-05-04 | Todd Harris | Co-Founder, President, CEO, Secretary, Treasurer & Director | Other Acquisition | +79,000 | -- |
| 2026-05-04 | Todd Harris | Co-Founder, President, CEO, Secretary, Treasurer & Director | Other Derivative Acquisition | +265,000 | $33.93 |
| 2026-05-04 | Bhavesh Ashar | Chief Operating Officer | Other Acquisition | +15,013 | -- |
| 2026-05-04 | Bhavesh Ashar | Chief Operating Officer | Other Derivative Acquisition | +50,295 | $33.93 |
| 2026-05-04 | Douglas Warner | Chief Medical Officer | Other Acquisition | +25,000 | -- |
| 2026-05-04 | Douglas Warner | Chief Medical Officer | Other Derivative Acquisition | +85,000 | $33.93 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
泰拉生物科学 讨论区 0 条评论